[1]
|
J. W. Nicholas and J. G. Breman, “Malaria and Babeiosis; Diseases Caused by Red Blood Cell Parasites in Harrisons Principle of Medicine,” McGraw Hill, New York, 2005, p. 1218.
|
[2]
|
N. Odebode and H. Shobiye, “Malaria Epidemics Loom as Parasites Develops Resistance to New Drug,” An Article in the Punch Newspapers Dated 12 July 2010.
http://www.punch ng.com
|
[3]
|
R. Ramachandra, “Resistance to Antimalarial Drugs Frontline,” Health (Indians National Magazine), 2004, pp. 34-37.
|
[4]
|
S. Ehrhardt and C. G. Meyer, “Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria,” Therapeutics and Clinical Risk Management, Vol. 5, 2009, pp. 805-815.
doi:10.2147/TCRM.S5375
|
[5]
|
WHO Report, “Roll Back Malaria Partnership; Facts on ACTs (Artemisinin Based Combination Therapies,” January 2006 Update. http://www.rollbackmalaria.org
|
[6]
|
Afrique en ligne, “Malaria Drug Resistance Warning Puts African Health Researchers on Edge,” Africa News, 2010. http://www.afriquejet.com
|
[7]
|
U. Rane and P. Sehdeu, “Malaria Drug Development,” 1993. http://www.aaas.org/international/Africa/malaria/rane.html
|
[8]
|
E. A. Ashley, K. Stepniewska and N. Lindeg?rdh, “Pharmacokinetic Study of Artemether-Lumefantrine Given Once Daily for the Treatment of Uncomplicated Multidrugresistant Falciparum Malaria,” Tropical Medicine and International Health, Vol. 12, No. 2, 2007, pp. 201-208. doi:10.1111/j.1365-3156.2006.01785.x
|
[9]
|
B. S. Kakkilaya, “Combinatios of Antimalarial Drugs,” Dr B.S. Kakkilaya’s Malaria Website, 2009.
|
[10]
|
WHO Report, “World Malaria Report,” 2008.
http://www.who.int/malaria/wmr
|
[11]
|
H. Myint, E. Ashley, N. Day, F. Nosten and N. White, “Efficacy and Safety of Dihydroartemisinin-Piperaquine,” Tropical Medicine and Hygiene, Vol. 101, No. 9, 2007, pp. 858-866. doi:10.1016/j.trstmh.2007.05.018
|
[12]
|
M. R. Kamya, A. Yeka, H. Bukirwa, M. Lugemwa and J. B. Rwakimari, “Artemether-Lumefantrine versus Dihydrortemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial,” PLoS Clinical Trials, Vol. 2, No. 5, 2007, p. e20.
|
[13]
|
M. Wilmer, Y. Laura, H. Ygor, A. Palacios, F. Eduardo, C. Cabezas, N. Arrospide, S. Guttierez and K. Trenton, “Efficacy and Tolerability of Artesunate plus Sulfadoxine-Pyrimethamine and Sulfadoxine Pyrimethamine Alone for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Peru,” American Journal of Tropical Medicine and Hygiene, Vol. 72, No. 5, 2005, pp. 568-572.
|
[14]
|
M. Meremikwu, A. Alaribe, R. Ejemot, A. Oyo-ita, J. Ekenjoku C. Nwachukwu, D. Ordu and E. Ezedinachi, “Artemether/Lumefantrine versus Artesunate plus Amodiaquine for Treating Uncomplicated Childhood Malaria in Nigeria: Randomized Controlled Trial,” Malaria Jour- nal, Vol. 5, No. 43, 2006, PMC Free Article.
doi:10.1186/1475-2875-5-43
|
[15]
|
P. Olumese, “Antimalarial Combination Therapy,” Capa- city Development and Technical Support, Roll Back Malaria, 2009. http://www.apps.who.inf/malaria
|